Effect of Neoadjuvant Therapy on Breast Cancer
Author Information
Author(s): J-C Gazet, RC Coombes, HT Ford, M Griffin, C Corbishley, V Makinde, S Lowndes, J Quilliam, R Sutcliffe
Primary Institution: Breast Research Unit, St. George's Hospital, London SWJ7, UK.
Hypothesis
Endocrine therapy might have a role in neoadjuvant therapy of breast cancer, provided that the ER status can be determined.
Conclusion
Neoadjuvant therapy based on estrogen receptor status can effectively downgrade breast cancer, increasing the opportunity for conservative surgery.
Supporting Evidence
- 47 patients with ER-positive tumors had a 40.4% response rate to endocrine therapy.
- 53 patients with ER-negative tumors had a 60% response rate to chemotherapy.
- 41% of early breast cancer patients achieved complete clinical resolution after chemotherapy.
Takeaway
Doctors gave different treatments to breast cancer patients based on whether their tumors were sensitive to hormones, and this helped many patients avoid more serious surgery.
Methodology
Patients were assigned to receive either chemotherapy or endocrine therapy based on their estrogen receptor status, and their responses were assessed after 3 months.
Limitations
The sample size for some comparisons was too small to allow valid statistical assessment.
Participant Demographics
Patients aged between 30 and 69, with a mean age of 54.02.
Statistical Information
P-Value
0.001
Statistical Significance
p=0.001
Want to read the original?
Access the complete publication on the publisher's website